Conduit Pharmaceuticals (CDT) Competitors $0.06 0.00 (-1.52%) (As of 05:36 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends CDT vs. NKGN, IBIO, EQ, MTEX, PULM, NNVC, CTXR, GOVX, INKT, and ATHAShould you be buying Conduit Pharmaceuticals stock or one of its competitors? The main competitors of Conduit Pharmaceuticals include NKGen Biotech (NKGN), iBio (IBIO), Equillium (EQ), Mannatech (MTEX), Pulmatrix (PULM), NanoViricides (NNVC), Citius Pharmaceuticals (CTXR), GeoVax Labs (GOVX), MiNK Therapeutics (INKT), and Athira Pharma (ATHA). These companies are all part of the "pharmaceutical products" industry. Conduit Pharmaceuticals vs. NKGen Biotech iBio Equillium Mannatech Pulmatrix NanoViricides Citius Pharmaceuticals GeoVax Labs MiNK Therapeutics Athira Pharma NKGen Biotech (NYSE:NKGN) and Conduit Pharmaceuticals (NASDAQ:CDT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, community ranking, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership. Do institutionals & insiders have more ownership in NKGN or CDT? 76.2% of NKGen Biotech shares are held by institutional investors. Comparatively, 3.3% of Conduit Pharmaceuticals shares are held by institutional investors. 74.7% of NKGen Biotech shares are held by insiders. Comparatively, 30.9% of Conduit Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media prefer NKGN or CDT? In the previous week, Conduit Pharmaceuticals had 4 more articles in the media than NKGen Biotech. MarketBeat recorded 4 mentions for Conduit Pharmaceuticals and 0 mentions for NKGen Biotech. Conduit Pharmaceuticals' average media sentiment score of 0.38 beat NKGen Biotech's score of 0.00 indicating that Conduit Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment NKGen Biotech Neutral Conduit Pharmaceuticals Neutral Does the MarketBeat Community believe in NKGN or CDT? Conduit Pharmaceuticals received 1 more outperform votes than NKGen Biotech when rated by MarketBeat users. CompanyUnderperformOutperformNKGen BiotechN/AN/AConduit PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo Votes Which has preferable valuation and earnings, NKGN or CDT? Conduit Pharmaceuticals has lower revenue, but higher earnings than NKGen Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNKGen Biotech$80K397.29-$82.94M-$5.08-0.18Conduit PharmaceuticalsN/AN/A-$540KN/AN/A Do analysts rate NKGN or CDT? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NKGen Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Conduit Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Is NKGN or CDT more profitable? Company Net Margins Return on Equity Return on Assets NKGen BiotechN/A N/A -479.36% Conduit Pharmaceuticals N/A N/A -328.67% Which has more volatility and risk, NKGN or CDT? NKGen Biotech has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500. Comparatively, Conduit Pharmaceuticals has a beta of 2.21, meaning that its share price is 121% more volatile than the S&P 500. SummaryConduit Pharmaceuticals beats NKGen Biotech on 8 of the 11 factors compared between the two stocks. Ad StocksToTradeTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’s promise, and a secret Elon project set to revolutionize a $23 Trillion market…Click here to review Tim’s special Holiday offer before it’s too late. Get Conduit Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CDT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDT vs. The Competition Export to ExcelMetricConduit PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.12M$6.69B$5.23B$9.26BDividend YieldN/A2.98%5.12%4.28%P/E RatioN/A10.6587.8717.28Price / SalesN/A208.071,162.56123.53Price / CashN/A57.1543.3837.82Price / Book-5.955.194.864.99Net Income-$540,000.00$151.58M$120.72M$225.21M7 Day PerformanceN/A3.87%2.88%4.63%1 Month PerformanceN/A-3.42%17.99%2.54%1 Year PerformanceN/A8.06%29.13%17.21% Conduit Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDTConduit PharmaceuticalsN/A$0.06-1.5%N/A-98.8%$5.99MN/A0.003Short Interest ↑Gap DownNKGNNKGen BiotechN/A$0.65+0.8%N/A-71.3%$22.81M$80,000.00-0.13N/AIBIOiBio1.3155 of 5 stars$2.43-2.0%$4.30+77.0%N/A$22.23M$175,000.000.00100Gap DownEQEquillium2.911 of 5 stars$0.61+0.3%$5.00+719.7%-1.7%$21.61M$45.91M-4.3640Short Interest ↓Gap DownMTEXMannatech0.2481 of 5 stars$11.40-4.0%N/A+42.2%$21.49M$121.55M-14.07250Gap UpPULMPulmatrix0.1432 of 5 stars$5.84-2.7%N/A+203.0%$21.33M$10.01M-2.2120Short Interest ↑Gap DownNNVCNanoViricidesN/A$1.52+1.7%N/A+39.8%$21.13MN/A-1.9920High Trading VolumeCTXRCitius Pharmaceuticals3.2836 of 5 stars$2.90+11.5%$100.00+3,348.3%-84.3%$20.96MN/A-0.4820Short Interest ↓GOVXGeoVax Labs2.7649 of 5 stars$2.20-3.9%$14.20+545.5%-58.7%$20.76M$3.09M0.0017Short Interest ↑INKTMiNK Therapeutics1.9439 of 5 stars$0.52-0.2%$6.50+1,142.8%-47.6%$20.69MN/A-1.3430Short Interest ↑Negative NewsATHAAthira Pharma3.4956 of 5 stars$0.52-10.5%$13.83+2,584.5%-74.9%$19.93MN/A-0.1840Short Interest ↓Positive News Related Companies and Tools Related Companies NKGen Biotech Alternatives iBio Alternatives Equillium Alternatives Mannatech Alternatives Pulmatrix Alternatives NanoViricides Alternatives Citius Pharmaceuticals Alternatives GeoVax Labs Alternatives MiNK Therapeutics Alternatives Athira Pharma Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CDT) was last updated on 12/26/2024 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | SponsoredElon Musk could help pay for your retirementElon Musk is the richest man in the world... And he's pouring trillions into a unique investment.Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conduit Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Conduit Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
